Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sandra L. Kweder"'
Autor:
Corinne S de Vries, Darcie Everett, Leyla Sahin, Robert Ball, Agnes Saint-Raymond, June Raine, Janet Nooney, John Clements, Wei Hua, Shannon Thor, Cosimo Zaccaria, Lynne Yao, Sandra L. Kweder
Publikováno v:
Clinical Pharmacology & Therapeutics. 110:941-945
Scientists and regulators in Europe and the United States continue to seek methods and strategies to improve knowledge on rational use of medicines for pregnant and breastfeeding populations, an important subset of women's health. Regulatory agencies
Publikováno v:
Expert Review of Clinical Pharmacology
There were no formal regulatory approvals for antivirals for the COVID-19 pandemic as of June 2020.We compare the first regulatory approvals for remdesivir, through emergency pathways available to three of the main regulators in the world, the U.S.,
Autor:
Gregory W. Daniel, Diane M. Maloney, David R. Joy, Elizabeth Richardson, Miranda J. Raggio, Sandra L. Kweder, Jonathan P. Jarow
Publikováno v:
Therapeutic Innovation & Regulatory Science. 52:793-798
Drug regulatory agencies around the world have implemented programs to expedite drug development and review for promising new products for serious diseases. These programs are all intended to minimize delays in patient access to innovative medicines,
Publikováno v:
Clinical Pharmacology and Therapeutics
There is talk of regulatory collaboration worldwide to protect public health and allow patients timely access to medicines. Here, we present the reality of the collaboration between the European Medicines Agency (EMA) and the US Food and Drug Adminis
Autor:
Jordi Llinares, Zahra Hanaizi, Sandra L. Kweder, Mwango Kashoki, Stella Yordanova, Christelle Bouygues, Richard Veselý
Publikováno v:
Clinical Pharmacology and Therapeutics
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have robust scientific and technical collaborations. As a window to the impact of these activities we compared the agencies' decisions on drug marketing applications. Deci
Autor:
Gerald G. Briggs, Sonia Hernandez-Diaz, Suzanne M. Gilboa, Phoebe Thorpe, Margaret A. Honein, Sandra L. Kweder, Janet D. Cragan, Jan M. Friedman, Jennifer N. Lind, Allen A. Mitchell
Publikováno v:
Pharmacoepidemiology and Drug Safety. 22:1013-1018
Purpose To determine which medications are most commonly used by women in the first trimester of pregnancy and identify the critical gaps in information about fetal risk for those medications.
Autor:
Sandra L. Kweder
Publikováno v:
Birth Defects Research Part A: Clinical and Molecular Teratology. 82:605-609
Autor:
Raymond O. Powrie, Sandra L. Kweder
Publikováno v:
de Swiet's Medical Disorders in Obstetric Practice, Fifth Edition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77176ce8e263242e71f5525760202cb9
https://doi.org/10.1002/9781444323016.ch30
https://doi.org/10.1002/9781444323016.ch30
Publikováno v:
Academic Medicine. 75:191-193
When they became aware that many of their internal medicine residents were not being routinely exposed to a representative range of medical illnesses in pregnancy, the authors set out to develop and implement a brief practical curriculum on the medic
Publikováno v:
Drug safety. 30(1)
The prescription of known teratogenic medications requires a careful balance between allowing women access to medications that they might need and avoiding unnecessary exposure to these medications during pregnancy because of their devastating fetal